Company intelligence / Profile preview
Campbell Neurosciences
Elk City, Idaho, United Statescampbellneurosciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Campbell Neurosciences has shown preclinical efficacy of its CampbellCell stem cell product in animal models of schizophrenia and bipolar disorder, as well as successful clinical validation of its saliva-based suicide risk diagnostic; no human clinical efficacy has yet been reported for its therapies but its diagnostic test has undergone clinical studies demonstrating high discrimination among risk groups.
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Cell therapyDiagnosticsNutraceutical
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Therapeutic Solutions International
Beyond the preview
Go deeper on Campbell Neurosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Campbell Neurosciences.